In Vitro Characterization of Inhalable Cationic Hybrid Nanoparticles as Potential Vaccine Carriers.
In Vitro Characterization of Inhalable Cationic Hybrid Nanoparticles as Potential Vaccine Carriers.
复制标题
可吸入阳离子杂化纳米粒作为潜在疫苗载体的体外表征。
DOI：
10.3390/ph14020164
复制
发表时间：
2021-02-18
期刊：
影响因子：
--
通讯作者：
Saleem IY
中科院分区：
文献类型：
--
作者：
Alfagih IM;Kaneko K;Kunda NK;Alanazi F;Dennison SR;Tawfeek HM;Saleem IY
本研究采用复乳溶剂挥发法制备了模型抗原--牛血清白蛋白(BSA)的PGA-co-PDL纳米粒。此外，将壳聚糖盐酸盐(CHL)引入到乳化溶剂法的外相中，使其表面吸附形成杂化阳离子CHL纳米粒子。将牛血清白蛋白包裹的CHL纳米粒包裹在由L-亮氨酸组成的纳米复合微载体中，通过喷雾干燥法制备了CHL纳米粒/NCMPS。考察了CHL NPs/NCMPS的体外雾化、释放、细胞存活率和摄取，以及蛋白质结构的稳定性。制备了粒径(480.2±32.2 nm)、电荷(+14.2±0.72 mV)、牛血清白蛋白负载量(7.2 8±1.3)µg/mg的杂化阳离子CHL纳米粒(CHL：10 mg/m L)。吸附模式符合Freundlich模型。CHL NPs/NCMPS的气雾化结果表明，微细颗粒含量(FPF：46.79±11.21%)和空气动力学质量中值直径(MMAD：1.49±0.29µm)。圆二色谱表明，从CHL NPs/NCMPS中释放出来后，牛血清白蛋白的α-螺旋结构保持不变。此外，树突状细胞(DC)和A549细胞显示出良好的存活率(2.5 mg/mLDCs作用4~24 h后，≥分别为70%)。共聚焦显微镜和流式细胞仪检测结果显示，杂化阳离子CHL纳米粒在孵育1h内被DC成功摄取。CD40、CD86和MHC-II细胞表面标志的上调表明，杂合阳离子CHL纳米粒成功地激活了DC。这些结果表明，CHL NPs/NCMPS技术平台可能被用于将蛋白质输送到肺部，用于免疫刺激应用，如疫苗。
In this study, PGA-co-PDL nanoparticles (NPs) encapsulating model antigen, bovine serum albumin (BSA), were prepared via double emulsion solvent evaporation. In addition, chitosan hydrochloride (CHL) was incorporated into the external phase of the emulsion solvent method, which resulted in surface adsorption onto the NPs to form hybrid cationic CHL NPs. The BSA encapsulated CHL NPs were encompassed into nanocomposite microcarriers (NCMPs) composed of l-leucine to produce CHL NPs/NCMPs via spray drying. The CHL NPs/NCMPs were investigated for in vitro aerosolization, release study, cell viability and uptake, and stability of protein structure. Hybrid cationic CHL NPs (CHL: 10 mg/mL) of particle size (480.2 ± 32.2 nm), charge (+14.2 ± 0.72 mV), and BSA loading (7.28 ± 1.3 µg/mg) were produced. The adsorption pattern was determined to follow the Freundlich model. Aerosolization of CHL NPs/NCMPs indicated fine particle fraction (FPF: 46.79 ± 11.21%) and mass median aerodynamic diameter (MMAD: 1.49 ± 0.29 µm). The BSA α-helical structure was maintained, after release from the CHL NPs/NCMPs, as indicated by circular dichroism. Furthermore, dendritic cells (DCs) and A549 cells showed good viability (≥70% at 2.5 mg/mL after 4–24 h exposure, respectively). Confocal microscopy and flow cytometry data showed hybrid cationic CHL NPs were successfully taken up by DCs within 1 h of incubation. The upregulation of CD40, CD86, and MHC-II cell surface markers indicated that the DCs were successfully activated by the hybrid cationic CHL NPs. These results suggest that the CHL NPs/NCMPs technology platform could potentially be used for the delivery of proteins to the lungs for immunostimulatory applications such as vaccines.
登录
查看更多内容
影响因子：
8
作者：
Fröhlich E
通讯作者：
Fröhlich E
影响因子：
14.8
作者：
Greenfield, Norma J.
通讯作者：
Greenfield, Norma J.
DOI：
10.1177/2051013613480144
发表时间：
2013-05-01
期刊：
Therapeutic advances in vaccines
影响因子：
--
作者：
Fox, Christopher B;Kramer, Ryan M;Vedvick, Thomas S
通讯作者：
Vedvick, Thomas S
DOI：
10.1016/j.jconrel.2005.02.027
发表时间：
2005-07-20
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
--
作者：
Kwon YJ;Standley SM;Goh SL;Fréchet JM
通讯作者：
Fréchet JM
用于癌症化疗的 DMAB 修饰多西他赛负载 PLGA-TPGS 纳米颗粒的口服给药
影响因子：
--
作者：
Chen, Hongbo;Zheng, Yi;Tian, Ge;Tian, Yan;Zeng, Xiaowei;Liu, Gan;Liu, Kexin;Li, Lei;Li, Zhen;Mei, Lin;Huang, Laiqiang
通讯作者：
Huang, Laiqiang